Boston Scientific Corp. (BSX) Tops Q2 EPS by 8c; Issues Outlook Above the Street
Boston Scientific Corp. (NYSE: BSX) reported Q2 EPS of $0.18, $0.08 better than the analyst estimate of $0.10. Revenue for the quarter came in at $1.81 billion versus the consensus estimate of $1.78 billion.
Boston Scientific Corp. sees Q3 2013 EPS of $0.14-$0.16, versus the consensus of $0.09. Boston Scientific Corp. sees Q3 2013 revenue of $1.7-1.76 billion, versus the consensus of $1.71 billion.
Boston Scientific Corp. sees FY2013 EPS of $0.67-$0.71, versus the consensus of $0.41. Boston Scientific Corp. sees FY2013 revenue of $7.05-7.17 billion, versus the consensus of $7.05 billion.
"We are pleased with our improved performance during the quarter," said Mike Mahoney, president and chief executive officer, Boston Scientific. "As we continue to expand our portfolio, our team is inspired to deliver meaningful innovation to more patients globally."
For earnings history and earnings-related data on Boston Scientific Corp. (BSX) click here.
Boston Scientific Corp. sees Q3 2013 EPS of $0.14-$0.16, versus the consensus of $0.09. Boston Scientific Corp. sees Q3 2013 revenue of $1.7-1.76 billion, versus the consensus of $1.71 billion.
Boston Scientific Corp. sees FY2013 EPS of $0.67-$0.71, versus the consensus of $0.41. Boston Scientific Corp. sees FY2013 revenue of $7.05-7.17 billion, versus the consensus of $7.05 billion.
"We are pleased with our improved performance during the quarter," said Mike Mahoney, president and chief executive officer, Boston Scientific. "As we continue to expand our portfolio, our team is inspired to deliver meaningful innovation to more patients globally."
For earnings history and earnings-related data on Boston Scientific Corp. (BSX) click here.